Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | FNTA | P49354 | 4/20 | 0.43 |
| ▸ | FNTB | P49356 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.42 |
| ▸ | SQLE | Q14534 | 2/20 | 0.41 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22372389 | 1.00 | ALOX15 (0.59) | ALOX15ALDH1A1KMT2AFNTAFNTB | |
| SCHEMBL22372388 | 1.00 | ALOX15 (0.59) | ALOX15ALDH1A1KMT2AFNTAFNTB | |
| SCHEMBL15914304 | 1.00 | ALOX15 (0.59) | ALOX15ALDH1A1KMT2AFNTAFNTB | |
| SCHEMBL9017126 | 1.00 | ALOX15 (0.59) | ALOX15ALDH1A1KMT2AFNTAFNTB | |
| SCHEMBL2004080 | 1.00 | ALOX15 (0.59) | ALOX15ALDH1A1KMT2AFNTAFNTB | |
| SCHEMBL9017160 | 1.00 | ALOX15 (0.59) | ALOX15ALDH1A1KMT2AFNTAFNTB | |
| SCHEMBL3506100 | 1.00 | ALOX15 (0.59) | ALOX15ALDH1A1KMT2AFNTAFNTB | |
| Linalyl Acetate SCHEMBL11793344 | 0.93 | ALOX15 (0.51) | ALOX15ALDH1A1KMT2AFNTAFNTB | |
| Linalyl Acetate SCHEMBL11793327 | 0.93 | ALOX15 (0.51) | ALOX15ALDH1A1KMT2AFNTAFNTB | |
| Linalyl Acetate SCHEMBL15745425 | 0.91 | ALOX15 (0.52) | ALOX15ALDH1A1CYP3A4KDM4EATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107815344-B | Environment-friendly semisynthetic cutting fluid and preparation method thereof | 广州市联诺化工科技有限公司 | 2020-08-25 | — | — | CN | claimed |
| US-20250261684-A1 | SMOKELESS TOBACCO PRODUCT FOR ORAL USE AND SOFT CAPSULE USED THEREIN | SUNSHO PHARMACEUTICAL CO., LTD. (JP) | 2025-08-21 | — | — | US | disclosed |
| US-12344569-B2 | Process for making a conjugated diene from an allyl alcohol | GIVAUDAN SA (CH) | 2025-07-01 | — | — | US | disclosed |
| WO-2025070466-A1 | SEAMLESS CAPSULE FOR ORAL CAVITY | 森下仁丹株式会社 | 2025-04-03 | — | — | WO | disclosed |
| EP-4420534-A1 | SMOKELESS TOBACCO PRODUCT FOR ORAL USE AND SOFT CAPSULE USED THEREIN | Sunsho Pharmaceutical Co., Ltd. (JP) | 2024-08-28 | — | — | EP | disclosed |
| EP-4168383-B1 | PROCESS FOR MAKING A CONJUGATED DIENE FROM AN ALLYL ALCOHOL | GIVAUDAN SA (CH) | 2024-07-31 | — | — | EP | disclosed |
| US-20240192184-A1 | DETECTION OF FLAVOUR LOSS | GIVAUDAN SA (CH) | 2024-06-13 | — | — | US | disclosed |
| CN-113316398-B | Seamless capsule, filter and smoking article comprising same | 三生医药株式会社 | 2024-06-11 | — | — | CN | disclosed |
| CN-118159258-A | Composition containing caryophyllene | 三生医药株式会社 | 2024-06-07 | — | — | CN | disclosed |
| US-20240180219-A1 | SEAMLESS CAPSULE STABLY DISINTEGRABLE EVEN IN HIGH-TEMPERATURE AND HIGH-HUMIDITY ENVIRONMENT, AND METHOD FOR PRODUCING THE SAME | MORISHITA JINTAN CO., LTD. (JP) | 2024-06-06 | — | — | US | disclosed |
| WO-2013002421-A1 | ANTIMICROBIAL COMPOSITION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-01-03 | — | — | WO | disclosed |
| US-7964637-B2 | Process for producing optically active theaspirane | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-06-21 | — | — | US | disclosed |
| US-20090270516-A1 | Process for Producing Optically Active Theaspirane | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2009-10-29 | — | — | US | disclosed |
| EP-2020225-A2 | Fragrance composition | Kao Corporation (JP) | 2009-02-04 | — | — | EP | disclosed |
| US-20050245407-A1 | Fragrance composition | KAO CORPORATION (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1552814-A1 | FRAGRANCE COMPOSITION | Kao Corporation (JP) | 2005-07-13 | — | — | EP | disclosed |
| US-4446125-A | Use of isomeric farnesene product-by-process for augmenting or enhancing the aroma or taste of foodstuffs, chewing gums, medicinal products and toothpastes | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1984-05-01 | — | — | US | disclosed |
| US-4391717-A | Use of isomeric farnesene product-by-process for augmenting or enhancing the aroma of perfume compositions, colognes and perfumed articles | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1983-07-05 | — | — | US | disclosed |
| US-4390444-A | PREPARED BY DEHYDRATING NEROLIDOL | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1983-06-28 | — | — | US | disclosed |
| US-4376068-A | Use of isomeric farnesene product-by-process for augmenting or enhancing the aroma of perfume compositions, colognes and perfumed articles | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1983-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12344569-B2 | Process for making a conjugated diene from an allyl alcohol | ADH1C, ADH1A, ADH5 | ALOX15 147/4885ALDH1A1 17/4885KMT2A 1850/4885 |
| US-20090270516-A1 | Process for Producing Optically Active Theaspirane | DHPS, ALDH7A1, FASN | ALOX15 389/4885ALDH1A1 38/4885KMT2A 1705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.